Your session is about to expire
← Back to Search
Larotrectinib for Childhood Cancer (SCOUT Trial)
SCOUT Trial Summary
This trial is testing the safety of a cancer drug called larotrectinib in children. The drug is designed to block the actions of genes in cancer cells. The trial will determine the dosage, how the drug is absorbed, and the response of different cancer types to the treatment.
SCOUT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SCOUT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
Frequently Asked Questions
How many participants are being monitored in this experiment?
"This clinical trial necessitates 155 volunteers who meet the outlined inclusion criteria. Those wishing to partake in this study can do so at British Columbia Childrens Hospital, located in Vancouver, or The Hospital for Sick Kids (SickKids) situated in Toronto."
What medical conditions can be benefited from the application of Larotrectinib (Vitrakvi, BAY2757556)?
"Larotrectinib (Vitrakvi, BAY2757556) can be administered to patients with ntrk3 fusion positive and ntrk2 fusion positive tumors of a solid nature."
Is this medical experiment actively seeking participants?
"Indeed, clinicaltrials.gov reveals that this medical study is open for recruitment and was initially published on December 16th 2015. Last updated November 14th 2022, the trial requires 155 participants to be recruited from 4 distinct sites."
Are there any Canadian medical centers conducting this experimental trial?
"Clinics in British Columbia, Toronto and Philadelphia are actively enrolling patients for this medical trial. Additionally, there is another 4 sites spread across the country that have opened recruitment to participants."
Has Larotrectinib (Vitrakvi, BAY2757556) been investigated in any additional clinical tests?
"Larotrectinib (Vitrakvi, BAY2757556) was initially trialled in 2015 at Alta Bates Summit Medical Center-Herrick Campus. There are 3 closed clinical trials and 8 active ones, many of which located in Vancouver, British Columbia."
Share this study with friends
Copy Link
Messenger